Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020
10 3월 2020 - 5:05AM
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage
pharmaceutical company focused on developing innovative and
differentiated prescription therapeutics for the treatment of
debilitating skin diseases, today announced that it will report its
fourth quarter and full year 2019 financial results after the close
of the U.S. financial markets on Wednesday, March 18, 2020.
Brickell’s management will host a conference call at 4:30 p.m. ET
to discuss the financial results and recent corporate highlights.
The dial-in number for the conference call is
1-877-705-6003 for domestic participants and 1-201-493-6725 for
international participants, with Conference ID #13700118. A
live webcast of the conference call can be accessed through the
“Investors” tab on the Brickell Biotech website at
http://www.brickellbio.com/. A replay will be available on
this website shortly after conclusion of the event for 90 days.
About Brickell
Brickell Biotech, Inc. is a clinical-stage
pharmaceutical company focused on developing innovative and
differentiated prescription therapeutics for the treatment of
debilitating skin diseases. Brickell’s pipeline consists of
potential novel therapeutics for hyperhidrosis and other prevalent
dermatological conditions. Brickell’s executive management team and
board of directors bring extensive experience in product
development and global commercialization, having served in
leadership roles at large global pharmaceutical companies and
biotechs that have developed and/or launched successful products,
including several that were first-in-class and/or achieved iconic
status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and
Juvederm®. Brickell’s strategy is to leverage this experience to
in-license, acquire, develop and commercialize innovative products
that Brickell believes can be successful in the currently
underserved dermatology global marketplace. For more information,
visit http://www.brickellbio.com.
Cautionary Note Regarding
Forward-Looking Statements
Any statements made in this press release
relating to future financial, business and/or research and clinical
performance, conditions, plans, prospects, trends, or strategies
and other such matters, including without limitation, the
anticipated timing, scope, design and/or results of future clinical
trials and prospects for commercializing any of Brickell’s product
candidates, including in Japan, the U.S. or any other country, are
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. In addition, when or if
used in this press release, the words “may,” “could,” “should,”
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,”
“predict” and similar expressions and their variants, as they
relate to Brickell, may identify forward-looking statements.
Brickell cautions that these forward-looking statements are subject
to numerous assumptions, risks, and uncertainties, which change
over time, often quickly and in unanticipated ways. Important
factors that may cause actual results to differ materially from the
results discussed in the forward-looking statements or historical
experience include risks and uncertainties, including without
limitation, ability to obtain adequate financing to advance product
development, potential delays for any reason in product
development, regulatory or law changes, unanticipated demands on
cash resources, risks associated with developing, and obtaining
regulatory approval for and commercializing novel therapeutics.
Further information on the factors and risks
that could cause actual results to differ from any forward-looking
statements are contained in Brickell’s filings with the United
States Securities and Exchange Commission (SEC), which are
available at http://www.sec.gov (or at http://www.brickellbio.com).
The forward-looking statements represent the estimates of Brickell
as of the date hereof only, and Brickell specifically disclaims any
duty or obligation to update forward-looking statements.
Brickell Investor Contact:Patti
BankManaging Director, WestwickeIR@brickellbio.com
Brickell Biotech (NASDAQ:BBI)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
Brickell Biotech (NASDAQ:BBI)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024